EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting androgen receptor ( AR ) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR ‐expressing prostate cancer cell lines

Mazdak Jamshidi, Fatemeh Keshavarzi iD, Sabrieh Amini, Ismail Laher, Ali Gheysarzadeh, Kambiz Davari

Cancer Reports · 2024

DOI: 10.1002/cnr2.1922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Mazdak Jamshidi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The androgen receptor (AR) has been studied as an approach to cancer therapy.

Aims

We used human breast cancer‐derived cells with high, low, and very low expression levels of AR, in addition to prostate cancer‐derived LNCaP and DU‐145 cells as a positive and negative controls to examine apoptosis caused by a synthetic peptide that targets ARs. Methods and Results The peptide was produced to inhibit AR transactivation in breast cancer cell lines. We then measured cell viability, caspase‐3 activity, and the ratio of Bax/Bcl‐2. The findings indicated that the peptide (100–500 nM) in the presence of dihydrotestosterone (DHT) reduced cell growth in cells with high and low expression level of AR ( p < .001), but not in cells with very low levels of AR. Treatment with 100–500 nM of peptide activated caspase‐3 and increased the ratio of Bax/Bcl‐2 in cells with high and low expression levels of AR. Also, increasing concentrations of the peptide (100–500 nM) reduced BrdU incorporation in the presence of DHT and promoted apoptosis in cells with high and low expression levels of AR ( p < .001).

Conclusion

The findings indicate the peptide significantly increased apoptosis in cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProstatic NeoplasmsMaleHumansReceptors, AndrogenCaspase 3bcl-2-Associated X ProteinDihydrotestosteroneApoptosisCell Line, TumorProto-Oncogene Proteins c-bcl-2

Stichwörter der Autor:innen

androgen receptoranticancer peptideapoptosisbreast cancerdihydrotestosterone (DHT)

Substanzen

Receptors, AndrogenCaspase 3bcl-2-Associated X ProteinDihydrotestosteroneProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran.
  • Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Clinical Biochemistry, Ilam University of Medical Sciences, Ilam, Iran.

ORCID-Profile: Fatemeh Keshavarzi

Zitieren

APA

Jamshidi, M., Keshavarzi, F., Amini, S., Laher, I., Gheysarzadeh, A., & Davari, K. (2024). Targeting androgen receptor ( AR ) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR ‐expressing prostate cancer cell lines. Cancer Reports. https://doi.org/10.1002/cnr2.1922

Vancouver

Jamshidi M, Keshavarzi F, Amini S, Laher I, Gheysarzadeh A, Davari K. Targeting androgen receptor ( AR ) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR ‐expressing prostate cancer cell lines. Cancer Reports. 2024. doi:10.1002/cnr2.1922

BibTeX
@article{Jamshidi2024,
  author = {Jamshidi, Mazdak and Keshavarzi, Fatemeh and Amini, Sabrieh and Laher, Ismail and Gheysarzadeh, Ali and Davari, Kambiz},
  title = {Targeting androgen receptor ( AR ) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR ‐expressing prostate cancer cell lines},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.1922}
}
Kostenlos starten →